- Global Pharma News & Resources

Human Papillomavirus (HPV) Infection Vaccines Market Can Grow by 2026 Due to Government Initiatives for Vaccinations, Industry Report Analysis, Growing Demand, Competitive Landscape, Leading Players, Regional Revenue

Global Human Papillomavirus (HPV) Infection Vaccines Market

Human papillomavirus infection is the most common sexually transmitted infection caused by HPV-related cancers, such as cervical and genital cancers. HPV infection vaccines are used in order to prevent genital wart, anal cancer, cervical cancer, and vaginal cancer. Three commercially available HPV prevention vaccines, such as Gardasil and Gardasil 9 by Merck & Co., Inc. and Cervarix by GlaxoSmithKline Plc, are proven to be highly effective in preventing HPV infection and genital precancerous lesions. The adoption of preventive vaccines shifted the paradigm of diseases, and are expected to have a major impact in reducing the burden of cervical cancer, HPV-associated malignancies, and benign tumors. The key factors driving growth of the human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.

Request for the trending sample of this report:

Global HPV Infection Vaccines Market Overview

A large number of clinical trials conducted by various pharmaceutical and biopharmaceutical companies are expected to fuel the growth of the global HPV infection vaccines market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Increasing research on therapeutic vaccines for the treatment of HPV infection to address the unmet medical needs is expected to boost the global market growth. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Furthermore, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated the Phase 3 clinical trial in June 2017.


Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Governmental and non-governmental organizations play an important role in increasing awareness through immunization programs, which in turn, favors the global market development. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Program was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to the American Society of Clinical Oncology (ASCO), an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. As reported by the World Health Organization (WHO) in 2014, HPV type 6 and type 11 are responsible for around 90% of the global anogenital wart cases.

Market Restrains

The global human papillomavirus infection vaccines market growth is likely to be restricted by the limited number of Food and Drug Administrations (FDA) approvals for commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. In addition, variable immunization coverage is estimated to impact the regional size. For instance, economies, such as the U.K and Mexico, has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.

To get detailed table of content (ToC), please click –

Global HPV Infection Vaccines Market – Regional Analysis

North America, followed by Europe, holds a major share of the human papillomavirus infection treatment vaccine market, owing to the high prevalence of cervical cancer in the region, local market players, and increasing governmental initiatives. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012. However, Asia Pacific is expected to witness significant growth during forecast period, due to awareness among the population for immunization.

Key Competitors

The major players operating in the global HPV infection vaccines market include Merck & Co., Inc. and GlaxoSmithKline plc. The companies having the candidate for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB, and ISA Pharmaceuticals.

Global HPV Infection Vaccines Market Taxonomy

By Product

  • Gardasil
  • Gardasil 9
  • Cervarix
  • Other Vaccines

By End-User

  • Hospitals
  • Clinics
  • Healthcare Centers
  • Other

Have a Look at Related Research Insights:




About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 09-Dec-2020